Lyell Immunopharma, Inc. — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
axicabtagene ciloleucelThis Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.	SEP	Phase 3	Thérapie cellulaire + Immunomodulation	United States	À vérifier
lisocabtagene maraleucelThis Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.	SEP	Phase 3	Thérapie cellulaire + Immunomodulation	United States	À vérifier
rondecabtagene autoleucelThis Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.	SEP	Phase 3	Thérapie cellulaire + Immunomodulation	United States	À vérifier
rondecabtagene autoleucelThis Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.	SEP	Phase 3	Thérapie cellulaire + Immunomodulation	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
rondecabtagene autoleucel	SEP	Phase 3	NCT07188558	PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.